CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York
Senior Management Team to Participate in Hanson Wade’s Inaugural NASH Summit in Boston
MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York City.
CohBar’s senior management team will also be participating in Hanson Wade’s NASH Summit in Boston April 4-6, 2017.
|
CohBar presentation details: |
|||
| Date: | Monday, April 3, 2017 | ||
| Time: | 3:40 pm EDT | ||
| Location: | St. Regis Hotel (Versailles Room), New York City | ||
About H.C. Wainwright & Co.’s NASH Investor Conference
This
inaugural, investor-focused event will feature presentations by public
and private biotech companies that are developing therapeutic treatments
for NASH, as well as panel discussions by renowned key opinion leaders
in the NASH field.
About Hanson Wade’s NASH Summit
This inaugural, scientific
and pharmaceutical community focused event will bring together leading
researchers and drug developers in the field of liver disease to share
ideas and discuss challenges and opportunities they face from drug
discovery to late stage clinical development.
About NAFLD and NASH
Non-alcoholic fatty liver disease
(NAFLD) is the buildup of extra fat in liver cells that is not due to
alcohol consumption and tends to develop in people who are overweight or
obese or have diabetes, high cholesterol or high levels of
triglycerides. Non-alcoholic steatohepatitis (NASH) is a more severe
form of NAFLD characterized by swelling of the liver that eventually may
lead to scarring (cirrhosis), and over time to liver cancer or liver
failure. NAFLD affects as much as 34% of the US population while as many
as 12% of US adults may have NASH. Currently, there are no FDA approved
treatments for NAFLD or NASH.
About CohBar’s Clinical Development Program
CohBar’s lead
clinical development program is based on MOTS-c, a mitochondrial-derived
peptide discovered in 2012 by the Company’s founders and their academic
collaborators, whose research has shown that MOTS-c plays a significant
role in the regulation of metabolism. The Company has developed
optimized analogs of the MOTS-c peptide, CB4209 and CB4211, as drug
candidates for advancement into IND-enabling activities. These drug
candidates have demonstrated significant therapeutic potential in
preclinical models for the treatment of obesity, with additional ongoing
studies to determine their therapeutic potential for the treatment of
nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver
disease, and as an add-on to other drugs for the treatment of type 2
diabetes.
About CohBar
CohBar (OTCQX: CWBR and TSXV: COB.U) is a
preclinical stage biotechnology company focused on the research and
development of mitochondria based therapeutics (MBTs), an emerging class
of drugs for the treatment of age-related diseases. MBTs originate from
the discovery by CohBar’s founders of a novel group of peptides within
the mitochondrial genome, which regulate metabolism and cell death and
whose biological activity declines with age. CohBar’s efforts are
focused on the development of these mitochondrial-derived peptides
(MDPs) into clinically relevant MBTs that offer the potential to address
a broad range of age-related diseases, including obesity, fatty liver
disease, type 2 diabetes, cancer, cardiovascular and neurodegenerative
disorders. To date, the Company and its founders have discovered more
than 50 biologically active mitochondrial peptides.
Forward-Looking Statements
This news release contains
forward-looking statements, including statements concerning the
company’s plans and prospects, including statements regarding potential
development of MBTs into disease therapeutics. These forward-looking
statements involve a number of risks and uncertainties including the
possibility of unfavorable research results and CohBar’s ability to
obtain capital, retain key personnel, expand its research operations,
and successfully advance its drug discovery and development
programs. Additional assumptions, risks and uncertainties are described
in detail in our registration statements, reports and other filings with
the Securities and Exchange Commission and applicable Canadian
securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future
performance and that our actual results may differ materially from those
set forth in the forward-looking statements. The forward-looking
statements and other information contained in this news release are made
as of the date hereof and CohBar does not undertake any obligation to
update publicly or revise any forward-looking statements or information,
whether as a result of new information, future events or otherwise,
unless so required by applicable securities laws. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For additional company information, please visit www.cohbar.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170329006237/en/
Investor and Media Contact:
CohBar, Inc.
Anna Schram,
650-446-7888 ext. 114
anna.schram@cohbar.com
Source: CohBar, Inc.
Released March 29, 2017